Chronic Myelogenous Leukemia in Childhood

Area of Science:

• Hematology
• Pediatric Oncology

Background:

• Chronic myelogenous leukemia (CML) is uncommon in children, necessitating adaptation of adult treatment protocols.
• Understanding pediatric CML requires comparing it with adult CML, focusing on therapeutic progress and unresolved questions.

Purpose of the Study:

• To review the similarities and differences between adult and pediatric CML.
• To highlight therapeutic advances in pediatric CML treatment.
• To identify emerging clinical questions in pediatric CML management.

Main Methods:

• Literature review focusing on pediatric and adult CML.
• Analysis of current therapeutic strategies, particularly tyrosine kinase inhibitors (TKIs).
• Examination of treatment outcomes and long-term effects.

Main Results:

• Tyrosine kinase inhibitors (TKIs) are effective for pediatric CML, allowing treatment without stem cell transplantation for newly diagnosed chronic phase patients.
• Available TKIs include imatinib, dasatinib, and nilotinib.
• Treatment-free remission, achievable in adults, is not yet supported in pediatrics outside clinical trials.

Conclusions:

• Targeted therapy with TKIs has significantly improved pediatric CML outcomes.
• Further research is needed on long-term TKI effects and the potential for treatment-free remission in children.
• Key questions remain regarding prolonged TKI exposure in young patients.